MedTrace Logo

Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma

NCT04422743 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-05-01

No results posted yet for this study

Summary

the general purpose of the study is to evaluate the potential beneficial effects of supplementation of a fixed combination of Citicoline 500 mg plus Homotaurine 50 mg on retinal ganglion cells (RGCs) function in subjects with glaucoma by pattern electroretinogram.

Conditions

Interventions

DIETARY_SUPPLEMENT

Citicoline 500 mg plus Homotaurine 50 mg

Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Principal Investigators

  • gemma caterina m Rossi · IRCCS Fondazione Policlinico San Matteo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-25
Primary Completion
2020-09-11
Completion
2020-09-11

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04422743 on ClinicalTrials.gov